Possible reasons include: first, the presence of a small number of prostate cancer cells that continue to secrete PSA; second, PDA is an aggressive subtype of prostate cancer that often exhibits partial resistance to conventional castration therapy, which may limit the extent of PSA reduction post-treatment. The gene discussed is KLK3; the disease is prostate carcinoma.